RemeGen Co., Ltd.
RemeGen Co., Ltd. (Yantai) is a biopharmaceutical company committed to the discovery, development, production and commercialization of first-in-class and best-in-class biological drugs.
Last updated October 1, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
RemeGen Co., Ltd. (Yantai) was co-founded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, and Dr. Jianmin Fang, a Canadian-American scientist. It is headquartered in Yantai, Shandong Province, China, with R&D centers and offices in China and the United States. The company is committed to the discovery, development, production and commercialization of first-in-class and best-in-class biological drugs, and has developed a series of innovative biologics with significant clinical value for major diseases such as autoimmunity, oncology, and ophthalmology. It is A+H dual-listed and reports 8 clinical pipelines, 40+ clinical trials, and 600+ patent applications.
History
RemeGen Co., Ltd. (Yantai) was co-founded in 2008 by Mr. Wang Weidong, founder of Rongchang Pharmaceuticals, and Dr. Jianmin Fang, a Canadian-American scientist. The company is headquartered in Yantai, Shandong Province, China, with R&D centers and offices in China and the United States. It is A+H dual-listed and reports 8 clinical pipelines, 40+ clinical trials, and 600+ patent applications.
- 2020
Mr. Wang Weidong became executive director in May.
- 2019
Mr. Wang Weidong became chairman of the board in June.
- 2013
Mr. Wang Weidong appointed as a director in October.
- 2008
RemeGen Co., Ltd. co-founded by Mr. Wang Weidong and Dr. Jianmin Fang in Yantai, Shandong, China.
Products and positioning
To become a domestic leading and international first-class biopharmaceutical company.
Telitacicept
A first-in-class fusion protein independently developed by RemeGen, targeting both BLyS and APRIL. Trade name: Tai'ai®; synonym: RC18.
Disitamab Vedotin
China's first original antibody-drug conjugate (ADC) and the first ADC in China to receive dual recognition as a breakthrough therapy from both the US FDA and the Chinese National Medical Products Administration. It is a HER2-targeted antitumor drug. Trade name: Aidixi®; synonym: RC48.
RC28
A dual-target VEGF/FGF innovative fusion protein product with the potential to be first-in-class, which has entered Phase 3 clinical study in the field of ophthalmic treatments.
Recent events
RemeGen closes approximately $100 million financing[6]
Reported:
RemeGen announced the closing of approximately US$100 million in private financing, co-led by Lilly Asia Ventures and Lake Bleu Capital. The proceeds were intended to support drug discovery, pipeline development, manufacturing-facility expansion and commercialization efforts for two lead molecules.
- Unconfirmed
Rongchang Biopharmaceutical completes funding round exceeding $100 million[7]
Reported:
Rongchang Biopharmaceutical completed a funding round of more than $100 million, led by Lilly Asia Ventures and Qingchi Capital, with other investors also participating.
Sources7 sources
Cite this profile: Cite the canonical profile. /brand-wiki/荣昌生物 · Editorial policy · How profiles are compiled